Enhance your nephrology practice with CME and tools focused on kidney medicine.
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, PhD, FRCP
Claudia Seikrit, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Advancing Patient-Centered, Guideline-Driven Management of Hyperkalemia in Adults With CKD and Associated Comorbidities
June 04, 2026
Glasgow
Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function
June 05, 2026
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
Ellie Kelepouris, MD, FACP, FAHA
CKD-aP Treatment Tool Kit
Leonie Kraft, MD
Emilio Sanchez, MD, PhD
Elevating CKD-aP Care: New Frontier
James Burton, DM, FRCP
Lucio Manenti, MD, PhD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Quantifying CKD-aP: Tools for Better Care
CKD-aP or Something Else? Decoding the Diagnosis
Kappa-Opioid Settings: Real-World Evidence Insights
Is CKD-aP Hiding in Your Dialysis Center?
Improving Sleep and Mental Health in Patients with CKD-aP
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Patrick Rossignol, MD, PhD
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Nihar R. Desai, MD, MPH
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Javed Butler, MD
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
The Critical Interplay: CKD, HF, and HyperkaleAmia
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Treatment Revolution in IgA Nephropathy
Shikha Wadhwani, MD
Dana Rizk, MD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.